Conversion Therapy of Intrahepatic Cholangiocarcinoma

Wang Zhiwei,Zheng Junling,Li Jiangtao,Peng Shuyou
DOI: https://doi.org/10.12287/j.issn.2096-8965.20200105
2020-01-01
Abstract:Intrahepatic cholangiocarcinoma (ICC) is one of the most common malignant liver tumors afterhepatocellular carcinoma, the incidence rate of which in our country is rather high. At present, surgical resection isstill main treatment for ICC. However, due to the lack of specific symptoms at early stage, ICC patients are oftendiagnosed at late stage and loss of the opportunity of surgical treatments. Conversion therapy is a novel conceptproposed recently. It demonstrated that malignant tumors that cannot be resected initially can be downsized by various treatments, so that patients obtained the chance of surgical treatments and get prolonged survival time. Withthe development of novel anti-tumor drugs, conversion therapy of ICC also is in the first flush of dawn. This review summarizes the current situation of ICC conversion therapy and our practical experience.
What problem does this paper attempt to address?